Filing summary
Issuer and period: The supplied filing is Tiger X Medical, Inc.’s Form 10-K for the fiscal year ended December 31, 2013, filed March 24, 2014. This does not match the request metadata naming BioCardia, Inc.; verify issuer identity before relying on this summary. The filing reports annual results, not a standalone fourth quarter.
Business context
Tiger X had sold substantially all of its reconstructive and spine division assets in 2011. Its remaining activities were collecting royalties from Arthrex, promoting the transferred products, seeking a partner or buyer for five retained patents, and evaluating future investment opportunities. The Arthrex agreement provides royalties of 5% of net sales for up to 20 years. The company reported one employee, its CEO and acting CFO, who received no salary.
Financial results and liquidity
| Metric | 2013 | 2012 |
|---|---|---|
| Royalty income | $268,000 | $62,000 |
| General and administrative expenses | $259,000 | $401,000 |
| Operating income (loss) | $9,000 | ($339,000) |
| Interest income | $10,000 | $8,000 |
| Continuing-operations income (loss) | $19,000 | ($331,000) |
| Discontinued-operations income | — | $636,000 |
| Net income | $19,000 | $305,000 |
| Cash from (used in) operating activities | $27,000 | ($310,000) |
| Cash at year-end | $13.295 million | $13.268 million |
Amounts are as reported; income-statement and cash-flow figures are in U.S. dollars. Operating margin was approximately 3.4% in 2013, based on royalty income. Year-end 2013 total assets were $13.328 million, liabilities $18,000, and stockholders’ equity $13.310 million. The filing reports no debt, no 2013 investing or financing cash flows, and no contractual obligations or off-balance-sheet financing. Management said cash was sufficient for needs over the next 12 months and beyond. No cash dividend was planned.
Changes, outlook, and risks
- Royalty income rose $206,000, which management attributed to higher Arthrex sales. G&A declined $142,000, mainly from lower outside accounting and legal fees and lower insurance expense.
- 2012 net income included $636,000 from discontinued operations, including a $532,000 tax benefit related to the prior asset sales. Thus, reported net income fell in 2013 despite improved continuing operations and operating cash flow.
- Management expected royalties to remain the primary revenue source and professional fees to stay at a reduced level. It gave no quantified revenue or earnings guidance.
- Principal risks include dependence on Arthrex royalties and possible disputes or offsets against payments; limited operating activities; difficulty funding or executing future investments; potential intellectual-property and legacy product-liability claims; and thinly traded penny-stock shares. Product-liability tail coverage was maintained, but the company warned it could become self-insured after the policy term.
- Disclosure controls and internal control over financial reporting were reported ineffective as of December 31, 2013, citing the lack of a full-time CFO, elimination of the internal accounting department, and insufficient segregation of duties. The independent auditor gave an unmodified opinion on the financial statements but did not audit internal-control effectiveness.
- Cash was concentrated at banks: balances exceeded the stated FDIC-insured amount by $13.053 million at year-end. Deferred tax assets of $4.775 million were fully offset by a valuation allowance.
Important facts to verify
- Confirm whether this Tiger X Medical 10-K is the intended filing; the request metadata identifies BioCardia.
- Review Arthrex royalty calculations, sales reporting, payment terms, and any contractual offsets.
- Assess the company’s plans and spending for its substantial cash balance, and the risk from uninsured bank deposits.
- Review the remediation status of ineffective disclosure controls and financial-reporting controls.
- Check remaining product-liability coverage, retained patent status, and any developments in claims or litigation.